

**ALEMBIC PHARMACEUTICALS LIMITED**

Regd. Office: Alembic Road, Vadodara 390 003

CIN: L24230GJ2010PLC061123

Ph: 0265-2280550 Fax: 0265-2282506

Email: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

Extract of Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31st December, 2017

(₹ in Crs. except per share data)

Particulars	Consolidated		
	Quarter Ended 31.12.2017	Nine Months Ended 31.12.2017	Quarter Ended 31.12.2016
Total Income from Operations	840.02	2,277.49	777.03
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	160.63	400.31	123.68
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	160.63	400.31	123.68
Net Profit for the period after tax (after Exceptional and/ or Extraordinary items)	130.60	318.83	86.55
Total Comprehensive Income for the period	130.98	316.71	86.11
Equity Share Capital	37.70	37.70	37.70
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	-	-	-
Earning Per Share (of Rs. 2/- each) Basic & Diluted	6.93	16.91	4.59
Research and Development Expenses	98.12	290.16	120.75

Notes:

1. Standalone details	Quarter Ended 31.12.2017	Nine Months Ended 31.12.2017	Quarter Ended 31.12.2016
Net Sales / Income from Operations	754.91	2,107.03	804.79
Profit Before Tax	133.77	356.71	174.05
Profit After Tax	105.04	277.80	137.83
Research and Development Expenses	95.24	278.05	103.20

2. The above is an extract of the detailed format of quarter and nine months ended reviewed financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarter and nine months ended reviewed financial results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

Place: Vadodara
Date: 31st January, 2018

Chirayu Amin
Chairman and CEO